Tue, February 21, 2012
Mon, February 20, 2012
Fri, February 17, 2012
Thu, February 16, 2012
Wed, February 15, 2012
Tue, February 14, 2012
Mon, February 13, 2012
[ Mon, Feb 13th 2012 ]: Market Wire
Rule 8.3- Xstrata Plc
Sun, February 12, 2012
Sat, February 11, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
Tue, February 7, 2012
Mon, February 6, 2012
[ Mon, Feb 06th 2012 ]: Market Wire
Form 8.3- Xstrata Plc
Sun, February 5, 2012
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
[ Thu, Feb 02nd 2012 ]: Market Wire
RAI Board Advisoryon Dividend
Wed, February 1, 2012
Tue, January 31, 2012
Mon, January 30, 2012
Fri, January 27, 2012
[ Fri, Jan 27th 2012 ]: Market Wire
Interim Management Statement
Thu, January 26, 2012

Murphy Analytics Initiates Coverageon Plandai Biotechnology Inc.

  Copy link into your clipboard //house-home.news-articles.net/content/2012/02/0 .. tiates-coverageon-plandai-biotechnology-inc.html
  Print publication without navigation Published in House and Home on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

February 09, 2012 08:30 ET

Murphy Analytics Initiates Coverage on Plandai Biotechnology, Inc.

Sets Target Price of $2.20 per Share

SEATTLE, WA--(Marketwire - Feb 9, 2012) - Plandaí Biotechnology, Inc. (OTCBB: [ PLPL ]) today announced that Murphy Analytics, LLC has initiated coverage of Plandaí and issued a buy recommendation with a twelve month price potential of $2.20 per share.

According to the research report prepared by Murphy, this valuation potential reflects the current value of plantation holdings of Plandaí, estimated at $50 million, the global market for green tea and green tea extracts, the profit projections prepared by Plandaí, and the trading value of companies within the industry. The report states, in part, the following:

With a near-term focus on food and beverage, wellness, cosmeceutical and nutraceuticals, Plandaí has access to very large and growing global markets. With a longer term focus on pharmaceuticals, targeting malaria in particular, Plandaí has a very attractive long-term opportunity to complement the Company's near-term target markets.

The global tea market is estimated at over $50 billion while Vitamin Shoppe estimates the U.S. nutritional supplements industry alone is over $29 billion, and growing at 5.4% per year. Driven by increasingly educated consumers, with a heighted focus on living longer, feeling younger, living healthy and naturally, GNC now generates $1.2 billion online and through 6,300 retail stores, serving as a barometer of the magnitude of the market opportunity.

Positive industry trends include an aging U.S. population, rising healthcare costs and the increased use of preventive measures. In addition, the increased focus on diet and nutrition, along with growing fitness and wellness program participation, serves as a positive trend for the nutritional supplements industry.

Commenting on Murphy's report, Plandaí chief executive officer Roger Duffield stated, "Murphy Analytics has a great reputation and we're pleased to see recognition of the market potential for Plandaí's technology. As we shift our focus towards production and marketing, we do so with the goal of maximizing shareholder value while also improving the health and welfare of millions of potential customers."

For a detailed review of the Murphy research report and valuation methodology, investors are directed to [ http://www.murphyanalytics.com/uploads/PLPL_Initiation.pdf ].

About Plandaí Biotechnology,Inc.
Plandaí Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principal holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement
This press release may contain forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company's actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making an investment decision.